Abstract. Excess manganese (Mn) in brain can be neurotoxic, implicated in several neurodegenerative disorders such as sporadic Alzheimer's disease (AD). However, little is known about the altered metal environment including elevated Mn in the progressive cognitive impairment of AD. Indeed, whether high Mn is associated with AD risk remains elusive. In the study, we recruited 40 Chinese elders with different cognitive statuses and investigated concentrations of Mn in whole blood and plasma amyloid-␤ (A␤) peptides. Surprisingly, there were significant correlations of Mn with Mini-Mental State Examination score and Clinical Dementia Rating Scale score. In addition, plasma A␤ peptides increased with elevated Mn. Further studies both in vitro and in vivo demonstrated dose-related neurotoxicity and increase of A␤ by Mn treatment, which was probably caused by disrupted A␤ degradation. These data suggested that high Mn may be involved in the progress of AD as an essential pathogenic factor.
INTRODUCTION
As an essential trace metal, manganese (Mn) is present in all tissues and is required for the maintenance of proper function and regulation of numerous biochemical and cellular reactions [1] . Mn is a cofactor or required metal ion for many enzymes such as superoxide dismutase [2] and polynucleotide phosphorylase [3] , and has important physiological roles, involved in immune function, regulation of metabolism, reproduction, digestion, bone growth, blood clotting, and brain development [4, 5] .
While Mn deficiency rarely occurs in humans, high Mn induced toxicity, in particular Mn neurotoxicity, is more prevalent [6, 7] . Cases of Mn neurotoxicity have been reported particularly in miners, smelters, and workers in the alloy industry where exposures occur predominantly via the inhalation of Mn fumes or Mncontaining dusts [8] . Chronic exposure to Mn leads to excessive Mn accumulation in the nervous system [9] , and dose-related cognitive deficits have been reported [10, 11] , which highlights Mn toxicity on cognitive function. Reports have shown that high Mn is implicated in several neurodegenerative disorders such as Parkinson's disease and Huntington's disease [12] [13] [14] .
What's more, Mn was shown significantly higher levels in the parietal cortex of the Alzheimer's disease (AD) brain [15] , and there was a significant inverse correlation of cerebrospinal fluid (CSF) amyloid-␤ (A␤) 42 with Mn [16] . Together, these studies suggest that high Mn could be a potential risk for AD.
Here in order to unfold the role of high Mn in the pathological process of AD, we measured concentrations of Mn in whole blood and neuropsychological tests in humans. We first found Mn in whole blood was inversely correlated with Mini-Mental State Examination (MMSE) score and positively correlated with plasma A␤ peptides, which drove our interest to Mn's role in A␤ related cognitive impairment. Then both in vivo and in vitro studies revealed dose dependent Mn neurotoxicity with A␤ level via disrupted A␤ degradation. What's more, with Mn chelation therapy, cognitive impairment was ameliorated in the AD model mice, which indicated a novel strategy for the intervention of AD pathogenesis.
MATERIALS AND METHODS

Subjects
All patients and age-matched controls from the Beijing Geriatric Hospital (Beijing, China) provided informed consent for study participation. For assessment of global cognitive impairment, all subjects received the standard neuropsychological tests, including the MMSE scores [17] and the Clinical Dementia Rating Scale (CDR) scores [18] , and divided into four groups accordingly [50, 51] as shown in Table 1 . Whole blood samples of 10 ml were obtained from veins and stored into standard commercial evacuated tubes containing sodium heparin at −80 • C until analysis.
Assay of metal ions
The total concentrations in human whole blood or the rodent brain of Mn, copper, mercury, and lead were determined by inductively coupled plasma-mass spectrometry (ICP-MS; Thermo X7, Thermo Elemental, Winsford, UK) in accordance with Gerhardsson and colleagues [20] . To ensure the accuracy of the analytical methods and results, samples with 2% HNO 3 and quality control (QC) samples were analyzed along with the collected samples (Seronorm Trace Elements Serum Lot MI0181; SERO AS, Billingstad). The background contamination of the collection vessels was below the detection level of the analytical method used, and the obtained values for the QC samples showed good agreement with the recommended concentrations.
Animals, housing and treatment
Male A␤PPswe/PS1dE9 transgenic mice (bought from Institute of Laboratory Animal Science, Chinese Academy of Medical Science, abbreviated as A␤PP mice for convenience), as an AD mice model, and age-matched wild-type mice were used. All work was approved by the Peking University Biomedical Ethics Committee Experimental Animal Ethics Branch. The animals were housed under controlled conditions of temperature and photoperiod, with free access to water and conventional mice chow. For Mn toxicity treatment, 27 mice of 12 ± 1 weeks old were used as follow: mice of low Mn group (n = 9) were treated with 15 mg/kg body weight, and mice of high Mn group (n = 9) with 60 mg/kg body weight, inorganic Mn (MnCl 2 ·4H 2 O, 99% purity; Sigma-Aldrich, St. Louis, MO, USA) dissolved in distilled water to 1 ml/kg administration volume; mice of the control group (n = 9) received distilled water, which naturally contains Mn about 5 ng/ml detected by ICP-MS. Administration was done by gavage, 5 days a week, and for 8 continuous weeks in total. For Mn chelation treatment, 16 mice of 6 months old were divided into two groups: one group of 8 mice was treated intraperitoneally four times weekly with 200 L 0.2 M Na 2 CaCDTA (Strem Chemical, Inc., MA01950) for 3 months, and the other received normal saline intraperitoneally.
Cell culture and treatments
Mouse N2a neuroblastoma cells stably expressing both wild type presenilin 1 (PS1wt) and Swedish mutant A␤PP (A␤PPsw) (abbreviated as A␤PPsw-N2a cells for convenience) were kindly provided by Drs. Sangram S. Sisodia, and SeongHun Kim (University of Chicago) [21] , and were maintained in normal DMEM free of Mn (Hyclone, South Logan, UT), and supplemented with 10% FBS. Cells were passaged at a ratio of 1:6 when 90% confluence had been reached and discarded after 20 passages. 24 h after splitting, the conditioned DMEM medium containing 10% FBS was replaced with fresh serum-free Mn-free DMEM (Hyclone). All experiments were performed in the absence of serum in order to exclude additional Mn 2+ from FBS. Manganese chloride (MnCl 2 ) was obtained from Sigma-Aldrich (St. Louis, MO). Cells were treated with different concentrations of 2+ ]o (0.0-400 M) for 12 h, 24 h, and 48 h. For MTT-reducing activity, the cells were then incubated with 0.5 mg/ml MTT (Sigma-Aldrich) at 37 • C for 4 h. Media were removed, and dimethyl sulfoxide (100 l) was added to each well to solubilize the formazan crystals generated by viable mitochondrial succinate dehydrogenase from MTT. The absorbance at 570 nm was measured using a VERSA MAX enzyme-linked immunosorbent assay reader (Molecular Devices, Sunnyvale, CA) as the MTT reducing activity of the cells. The resultant data were expressed as the percentage of viable cells relative to controls.
Lactate dehydrogenase (LDH) assay
LDH release is an indicator of the integrity of cell membrane in that LDH releases from cells after cells were injured. After Mn treatments, LDH releases in the medium were measured as previously described [49] . The values of absorbance were read at 440 nm by the use of the microplate reader (Molecular Devices, Sunnyvale, CA). The resultant data were expressed as the percentage of viable cells relative to controls.
Quantification of plasma, medium and brain Aβ peptide levels by sandwich enzyme-linked immunosorbent assay (ELISA)
For plasma A␤, a 2-ml sample of venous blood was split and centrifuged at 1,000 g for 10 min at 4 • C. For medium A␤, following the 24 h treatment with varying [Mn 2+ ], cells and conditioned media were harvested. Complete Protease Inhibitor cocktail was added to the medium to prevent degradation of A␤ protein and the cell debris was removed by centrifugation at 3,000 g for 10 min at 4 • C. For brain A␤, half of fresh-frozen mouse brain was serially homogenized into detergent-soluble and guanidine HCl-soluble fractions as described [22] . All samples were assayed for A␤ 40 and A␤ 42 by sandwich ELISA according to the manufacturer's instructions (Biosource International, Camarillo, CA). The detection limit for this assay was 5 pg/ml for A␤ 40 and 10 pg/ml for A␤ 42 . The A␤ concentration in the medium was normalized based on the amount of cells in each culture (as determined by protein content in the cell lysates). All measurements were performed in duplicate.
Western blot analysis
Brains and cells were harvested and lysed on ice in western blot lysis buffer containing 50 mM TrisHCl, pH 6.8, 8 M urea, 5% ␤-mercaptoethanol, 2% SDS, and protease inhibitors. The lysates were collected, centrifuged at 12,000 g 4 • C for 5 min, and quantified for total proteins by the BCA protein assay kit. For western blot analysis, total proteins were separated on 10% T 5% C Bicine/Tris, 8 M urea, SDS-PAGE or 10-18% regular SDS-PAGE system [23, 24] . Protein was transferred to 0.45 m polyvinylidene difluoride membranes (Immobilon-P; Millipore, Bedford, MA), blocked for 1 h in 5% (m/v) nonfat milk in Tris-buffered saline (TBS, pH 7.5), supplemented with 0.1% Tween 20. Antibodies and their dilutions used in this study include 6E10 (1:1000, COVANCE) or A8717 (1:10000, Sigma) for A␤PP derivatives, NEP-specific mAb (1:1000, R&D), IDE pAb (1:5000, EMD Millipore) and anti-␤-actin mouse mAb (1:5000, Sigma) as an internal reference control. Following incubation with the appropriate horseradish peroxidase-conjugated secondary antibody for 1 h at ambient temperature, the immunoblots were developed using the ECL system. Quantitative densitometric analyses were performed on digitized images of immunoblots with Quantity One software (Bio-Rad, Hercules, CA). The ␥-secretase inhibitor DAPT (500 nM, 8 h treatment) was employed in the experiments as a positive control for CTF␣ and CTF␤. Representative blots from at least three independent experiments are shown.
RT-PCR analysis
Total RNA was extracted with TRIZOL (Invitrogen) and converted to cDNA by reverse transcriptase using random hexamers to prime superscript III RNasefree reverse transcriptase (Invitrogen) according to the manufacturer's instructions. Each RT-PCR primer used in this study was as follows; neprilysin sense primer, 5 -AGCCTCTCTGTGCTTGTCTTGC-3 ; neprilysin antisense primer, 5 -CACTCATAGTAGCCTCTG GAAGGG-3 ; ␤-actin sense primer, 5 -TGTACG CCTCTGGCCGTAC-3 ; ␤-actin antisense primer, 5 -CCACGTCACACTTCATGATGG-3 ; insulin degrading enzyme (IDE) sense primer, 5 -CCCACC ACAGACAAGTCCTC-3 ; IDE antisense primer, 5 -AAAACTGCGCAAACCTGTCC-3 . PCR reactions were performed at 94 • for 30 s, 55 • for 1 min, and 68 • for 2 min during 40 cycles, followed by a final extension of 7 min at 68 • [25] . Additionally, the resulting PCR products were analyzed on a 1% agarose gel stained with ethidium bromide.
Morris water maze test
Behavior was performed with a modified version of the Morris water maze used to assess spatial navigation learning and memory retention as before [26, 27] with minor modifications.
Initially, animals received a habituation trial during which the animals were handled for several minutes by the experimenter and allowed to explore the pool of water (diameter 150 cm, height 40 cm, temperature 23 ± 1 • C) without the platform present. Following habituation, visible platform training was performed for 2 consecutive days to measure motivation of the mice to find a platform, visual acuity of the mice, and the ability of mice to use local cues. In the acquisition phase, we measured the ability of mice to form a representation of the spatial relationship between a safe, but invisible (submerged 1 cm below the water level), platform (10 cm in diameter) and visual cues surrounding the maze. Animals were allowed 60 s to locate the platform and 20 s to rest on it. Mice that failed to find the platform were led there by the experimenter and allowed to rest there for 20 s. Twenty-four hours following the last acquisition trial; a single 60 s probe trial was administered to assess spatial memory retention. For the probe trial, animals were returned to the maze as during training, but with no platform present, and parameters were recorded to assess the ability of the mouse to remember the previous location of the platform.
During the acquisition phase, escape latency (acquisition time to reach the platform) and path length (distance swam to the platform) were used to analyze and compare the performance between different treatment groups. The time spent in each of the four quadrants, the number of crossings of the former platform location, time to the former platform location, time to the platform quadrant, and the number of entries into the target quadrant were recorded and analyzed during the probe trials.
Statistical analysis
Analyses were conducted using the GraphPad Prism 5 for Windows (GraphPad Software, San Diego, CA). As most of the variables showed a skewed distribution (checked by normal probability plots), nonparametric statistical processing was applied (Kruskal-Wallis one-way analysis of variance, Mann-Whitney U test, Spearman's correlation coefficients). Comparisons between multiple groups were made by one-way ANOVA followed by Dunnett's Multiple Comparison Test, and the Student's t test was used for comparisons between two groups. P values <0.05 were regarded as statistically significant (two-tailed tests).
RESULTS
Manganese in whole blood with different cognitive statuses
Demographic data for the four groups with different cognitive statuses are shown in Table 1 . Concentrations of Mn in whole blood of all subjects were measured and analyzed: CDR 0 (age-matched healthy control, n = 10) 11.20 ± 0.95 ng/ml; CDR 0.5 (Mild Cognitive Impairment, n = 10) 12.37 ± 1.08 ng/ml; CDR 1 (Mild dementia, n = 4) 9.63 ± 1.11 ng/ml; CDR >2 (dementia, n = 16) 13.98 ± 0.88 ng/ml (Fig. 1A) . A significant change in Mn concentration was observed among four groups (F (3,36) = 2.925, p = 0.0469), and there were significant changes between CDR >2 and CDR 0 (p = 0.0293) and between CDR >2 and CDR 1 (p = 0.0309) (Fig. 1A) . After the correlative analysis with MMSE and CDR scores, regardless of the grouping factor, we surprisingly discovered that there was a significant inverse correlation between MMSE score and Mn level (p = 0.0339, R 2 = 0.1191) (Fig. 1B) , and a positive correlation between CDR score and Mn level (p = 0.0482, R 2 = 0.0989) (Fig. 1C) . Concentrations of other neurotoxic metals (copper, mercury, and lead) [28, 29] had also been measured, but none had a significant association with MMSE scores (Fig. 1D) . These results suggested that Mn might be strongly related to the progressive cognitive impairment. Indeed, more cases and follow-up evaluations are needed.
Manganese in whole blood with plasma Aβ peptides
Plasma A␤ peptides, especially A␤ 42 , were potential risk biomarkers of AD [30, 31] . Here we demonstrated that in all subjects plasma A␤ 42 was inversely correlated with MMSE (p < 0.01, Fig. 2A ), but plasma A␤ 40 was not (p > 0.05, Fig. 2C ). Interestingly, when analyzed with concentrations of Mn, both plasma A␤ 42 and A␤ 40 were increased with elevated Mn (p < 0.01 for A␤ 42 , Fig. 2B ; p < 0.05 for A␤ 40 , Fig. 2D ), which suggested that Mn might play a causal role in A␤ metabolism.
Exposure to high manganese induced Aβ related neurotoxicity and cognitive impairment
We investigated the effects of high Mn on A␤ release in cultured neuronal cells for its neurotoxicity. MTT assay for cell viability demonstrated dose and time dependent toxicity of exposure to high Mn (Fig. 3A) . LDH assay was used to assess the cell membrane integrity, and we found that after Mn treatment, LDH release was significantly increased only at 200 M for 48 h and 400 M for 12-48 h (Fig. 3B) . These data revealed that after 200 M Mn treated for 24 h, cell viability was decreased but cells did not undergo necrosis. Further, levels of A␤ 40 and A␤ 42 in the medium were measured (Fig. 3C, D) , and both were found to sig- Fig. 2 . Elevated manganese (Mn) with increased plasma A␤ 42 and A␤ 40 . A, C) Graphic representation of partial regression graph for plasma A␤ 42 and A␤ 40 with MMSE scores (p < 0.01 for A␤ 42 and p > 0.05 for A␤ 40 , n = 40). Only plasma A␤ 42 showed negative correlation with MMSE scores. B, D) Graphic representation of partial regression graph for Mn in whole blood with plasma A␤ 42 and A␤ 40 (p < 0.01 for A␤ 42 and p < 0.05 for A␤ 40 , n = 40). Mn was positively correlated with both plasma A␤ 42 and A␤ 40 . MMSE, Mini Mental Status Examination. nificantly increase in response to high Mn for 24 h at 200 and 400 M. These data revealed that Mn induced neurotoxicity was, at least partially, due to the elevated A␤ level. Evidence had shown significant higher Mn levels in the parietal cortex of the AD brain [15] , then based on our in vivo study, we demonstrated Mn neurotoxicity in A␤PPsw/PS1dE9 transgenic mice (A␤PP mice), a mouse model for AD. Male A␤PP mice at age 12 weeks were fed low dose of Mn (Low Mn) or high dose of Mn (High Mn) for 8 weeks, and compared to age-matched A␤PP mice on a normal diet (Control). During the Morris water maze acquisition test (Fig. 4A) , Low Mn group performed worse at day 2 and day 6, High Mn group performed worse from day 2 to 6 compared to Control group, and High Mn group performed even worse than Low Mn group at day 6. Indeed, there was a significant treatment effect on escape latency (F (2,144) = 23.62, p < 0.0001) (Fig. 4A) , accompanied by dose dependent decrease of time spent in target quadrant during the probe trial test (Fig. 4B,  C) , which revealed a dose related Mn toxicity on cognitive function.
To examine whether the impaired cognitive function in Mn treated A␤PP mice might be due to increased A␤ load in the brain, A␤ content in the brain-soluble and brain-insoluble fractions was quantified. The levels of soluble and insoluble A␤ 40 and A␤ 42 in Low Mn and High Mn mice brain were significantly higher than those in Control mice, and significant differences ]o for 24 h. Cell lysates were immunoblotted for NEP or IDE and ␤-actin was used as a loading control. NEP and IDE mRNA levels were quantitated by RT-PCR and normalized to ␤-actin controls and expressed as ratios of control cell levels. Data are mean ± SEM (error bars) (n = 4); *p < 0.05; **p < 0.01. NEP, neprilysin; IDE, insulin degrading enzyme. 40 and A␤ 42 concentrations. Both Triton-X-soluble (C) and -insoluble (guanidine extract) (D) A␤ were measured (n = 6). E) Representative western blots and quantitative analysis of NEP and IDE in brains of two groups (n = 6 for each group). F) Concentration of Mn in brains of WT and A␤PP mice at the age of 3, 6 and 9 months (n = 6). G) Concentration of Mn in brains of A␤PP and A␤PP+Mn chelator mice (n = 6). Data are mean ± SEM (error bars). *p < 0.05; **p < 0.01; ***p < 0.001. A␤PP, the A␤PPsw/PS1dE9 transgenic mice; A␤PP+Mn chelator, A␤PP mice treated with Na 2 CaCDTA; NEP, neprilysin; IDE, insulin degrading enzyme.
of soluble A␤ 40 , soluble A␤ 42 , and insoluble A␤ 42 were observed between Low Mn and High Mn mice (Fig. 4D, E) . Furthermore, there was a negative correlation of the level of brain soluble A␤ 40 , soluble A␤ 42 , and insoluble A␤ 42 with the probe trial performance of mice of Mn exposure, suggesting a causative relation between the increased A␤ and the aggravated cognitive impairment (Fig. 4F-H) .
High manganese did not affect Aβ production, but impaired Aβ degradation
To clarify how high Mn induced elevation of A␤ level, we compared amyloid-␤ precursor protein (A␤PP) processing for A␤ production among differed concentrations of Mn. However, as shown in Fig. 5A , increased Mn changed neither the level of full-length A␤PP (flA␤PP) nor its processing production CTF␣ and even CTF␤ in cultured cells, which suggested high Mn had no impact on A␤ production. Then we examined two major enzymes of A␤ degradation, namely neprilysin (NEP) and insulin degrading enzyme (IDE). Surprisingly, NEP protein level decreased slightly but significantly by 14% at 200 M and 21% at 400 M of Mn exposure (Fig. 5Ba,  b) , and IDE protein level decreased more significantly by 31% at 200 M and further 43% at 400 M of Mn exposure (Fig. 5Ca, b) , which indicated disrupted A␤ degradation metabolism induced by high Mn. Levels of mRNA showed consistent results (Fig. 5Bc, Cc) , which suggested a novel role of Mn as a transcription regulator.
After Mn treatment, A␤PP processing remained unchanged in brains of Low Mn and High Mn group mice, compared to Control group (Fig. 6, two upper  panels) . Nevertheless, there were dose dependent decreases of NEP and IDE (Fig. 6 , two middle panels): NEP decreased by 31% in Low Mn group and 51% in High Mn group, and IDE decreased by 16% in Low Mn group and 34% in High Mn group. In addition, NEP and IDE were both reduced in High Mn group, compared to Low Mn group (Fig. 6) . Combined with the in vitro study above, it could be concluded that Mn overload caused down-regulation of A␤ degradation enzymes.
Manganese chelation therapy ameliorated cognitive impairment in the AD model mice
Data above made us wonder whether reducing brain Mn level can be a potential therapeutic strategy for AD. Compared to age-matched wild type mice, brain Mn level of A␤PP mice stayed normally at the age of 3 and 6 months but increased significantly at the age of 9 months (Fig. 7F) . Then we treated 6-month-old A␤PP mice intraperitoneally with Mn chelator Na 2 CaCDTA for 3 months. Surprisingly, after Mn chelator treatment, A␤PP mice performed better during the acquisition test (Fig. 7A ) and the probe trial test (Fig. 7B) of Morris water maze. Further, soluble and insoluble A␤ 40 and A␤ 42 were reduced (Fig. 7C, D) , along with elevated NEP protein level by 30% and IDE protein level by 74% (Fig. 7E) , which revealed rescue of Mn chelation therapy on A␤ related cognitive impairment. Additionally, brain Mn was detected and also reduced after Mn chelation (Fig. 7G ).
DISCUSSION
Mn in the blood as a tracker for the progressive cognitive impairment
An imbalance in Mn homeostasis is well known to result in severe CNS dysfunction [6] . Increased Mn concentrations in the brain can occur under a variety of conditions, such as occupational, iatrogenic, medical, and environmental exposures [32] . After oral Mn intake, the blood-CSF barrier might be the major route for Mn into the brain [6] . The homeostasis of Mn in the CSF appears to be directly influenced by plasma Mn concentrations [33] . When testing several possible Mn carriers, the most abundant Mn species was Mncitrate [34] . Elevated Mn-Citrate in serum could be a valuable marker for increased total Mn in CSF (and brain), i.e., it could be a marker for elevated risk of Mn-dependent neurological disorders in occupational health [35] . Then the metal environment in the blood may be an efficient indicator for the CSF condition and the related pathological status.
In our study, the concentrations of Mn in whole blood of patients were significantly negatively related to the MMSE scores and positively related to the CDR scores of elder subjects with different cognitive statuses, which indicated that Mn in whole blood may track the progressive cognitive impairment of AD. Mn in whole blood was also positively correlated with plasma A␤ peptides, the potential risk biomarkers of AD, which suggested the possible role of Mn in A␤ hallmarked AD. Reports had demonstrated that Mn showed significantly higher levels in the parietal cortex and plasma of AD in humans [15, 20] , and diffused A␤ plaques were also found in the frontal cortex from Mnexposed non-human primates [36] . Besides, exposure to Mn can cause the hyperphosphorylation of tau [37] , which may lead to the formation of neurofibrillary tangles, one of the key clinical structure changes of AD. In summary, Mn in whole blood may be a potential noninvasive biomarker for AD.
High Mn induced Aβ related neurotoxicity on cultured neurons and rodent brains
Chronic occupational exposure to Mn mostly by inhalation raises its accumulation in the central nervous system, especially in the basal ganglia, leading to degeneration of neurons and a loss of dopamine [34, 38] . Several mechanisms underlie its neurotoxicity. For example, inhibitory effect of Mn on AChE activity promotes increased neuronal oxidative stress and neuroinflammatory biomarkers [39] . Also Mninduced neurotoxicity is associated with disruption of the glutamine/glutamate-c-aminobutyric acid cycle between astrocytes and neurons [40] . Besides neurons [38, 41] , increasing studies focus on its activity/toxicity on astrocytes [8, [42] [43] [44] , the blood-brain barrier [45] and the blood-CSF barrier [6, 46] .
Here we examined Mn neurotoxicity with MTT assay, and found a dose and time dependent manner. Also, the released cellular A␤ peptides, which were initially neurotoxic, were increased after high Mn exposure, indicating a non-ignorable role of elevated A␤ level in Mn induced neurotoxicity. Further our in vivo study found dose related cognitive impairment in the AD model mice after Mn treatment. Both brain-soluble and brain-insoluble A␤ peptides were increased and had a strong relationship with the probe trial performance, which suggested that high Mn could induce A␤ related cognitive impairment. The Mn chelation therapy supported us a novel strategy to prevent and treat AD. After intraperitoneal injection, Mn chelator Na 2 CaCDTA reduced the concentration of Mn in the brain, and restored the cognitive function of AD model mice, along with decreased A␤ peptides. Indeed, the application dosage of Na 2 CaCDTA had no effects on wild type mice (not shown).
High Mn impaired Aβ degradation but not Aβ production
A␤ is generated from sequential cleavages of the A␤PP by the ␤-and ␥-secretases [47] , and is removed through various clearance pathways and by enzyme-mediated degradation, mainly including the metalloproteases NEP and IDE [48] . We probed into effects of high Mn on A␤PP processing for A␤ generation, but it did not differ among all concentrations of Mn exposure, while NEP and IDE decreased after high Mn exposure in cultured neurons. Furthermore, NEP and IDE were dose dependently reduced in Mn-treated mice, indicating disrupted A␤ degradation metabolism induced by high Mn. Evidence has shown that Mn can act as the metal cofactor of polynucleotide phosphorylase and affect the discrimination of RNA from DNA [3] , and then Mn homeostasis might regulate the related protein level at the transcriptional level.
In conclusion, we first found Mn in whole blood was correlated with MMSE/CDR scores and plasma A␤ peptides, and high Mn could induce A␤ related cognitive impairment via disrupted A␤ degradation. Our results suggest that high Mn may be a risk and an essential pathogenic factor for AD.
